The present study indicates that survival outcomes are similar between liquid biopsy and tissue biopsy, suggesting that liquid biopsy is a promising modality for early detection of EGFR mutations in advanced NSCLC, especially in parts of globe where EGFR mutation rate is high. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.